reports
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Genmab Announces Completion of Tender Offer for Outstanding Common Sha...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidia...
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 11, 2025 – (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click . An archive of the webcast will be available on Genmab’s website. This meeting is not an official program of the ASH Annual Meeting. About Genmab Genmab i...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting P...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstra...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R2 aloneEPKINLY + R2 was recently approved by the U.S. F...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment ...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLB...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Genmab Announces Closing of Private Offering of Senior Secured Notes a...
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offe...
Transactions With Shares and Linked Securities in Genmab A/S Made by M...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 1, 2025 – (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their beh...
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Mowi ASA – Successful placement of new senior unsecured green bonds
Mowi ASA – Successful placement of new senior unsecured green bonds Bergen, 27 November 2025 – Reference is made to the stock exchange notice from 25 November 2025. Today, Mowi ASA (rated BBB+/Stable by Nordic Credit Rating) successfully issued a total of NOK 4,500 million (EUR 382 million) of new senior unsecured green bonds split between two tranches. NOK 3,500 million (EUR 297 million) has been issued with a tenor of 5 years and a coupon of 3-month Nibor + 1.10% margin p.a., and NOK 1,000 million (EUR 85 million) has been issued with a tenor of 5 years and a fixed coupon of 4.95% p.a. (e...
- Alexander Aukner
Mowi (OSE:MOWI): Share purchase program for employees in Mowi
Mowi (OSE:MOWI): Share purchase program for employees in Mowi The Board of Directors of Mowi ASA (the "Company") has resolved to offer all permanent employees in the Company and its Norwegian, Scottish, Canadian and Polish subsidiaries the opportunity to purchase shares in the Company at a discounted price. The offer to employees is based on the average purchasing price for the Company's shares on 26 November 2025 of NOK 222.22 per share. Based on the above, eligible employees were presented with three alternative offers: Alternative 1: Purchase 45 shares at a value of approximatel...
- ABGSC Strategy Research
- Bengt Jonassen
Mowi ASA – Green Bond Mandate Announcement and Fixed Income Investor M...
Mowi ASA – Green Bond Mandate Announcement and Fixed Income Investor Meetings Bergen, 25 November 2025. Mowi ASA, investment grade rated BBB+ with stable outlook by Nordic Credit Rating, has mandated Danske Bank, DNB Carnegie and Nordea as Global Coordinators and Joint Lead Managers, and ABN AMRO, Crédit Agricole Corporate and Investment Bank, Rabobank and SEB as Joint Lead Managers to arrange a series of physical and virtual fixed income investor meetings commencing today. One or more NOK-denominated senior unsecured green bond issues (swapped to EUR) with a minimum tenor of 5 years may...
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare...
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami Media ReleaseCOPENHAGEN, Denmark; November 24, 2025 (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare Conference in Miami at 9:45 AM EST (3:45 PM CET) on December 4, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients w...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- Alexander Aukner
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.